Señales en vivo de IMMP | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 14:20):

Stats
Volumen de hoy	404 185
Volumen promedio	178 114
Capitalización de mercado	327.36M
EPS	$0 ( 2023-09-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.66
ATR14	$0.00800 (0.30%)

Volumen Correlación

Largo: -0.21 (neutral)

Corto: -0.30 (neutral)

Signal:(59.375) Neutral

Immutep Limited Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immutep Limited Correlación - Moneda/Commodity

0.02
( neutral )

-0.01
( neutral )

0.00
( neutral )

0.28
( neutral )

-0.21
( neutral )

Immutep Limited Finanzas

Annual	2023
Ingresos:	$3.51M
Beneficio Bruto:	$1.44M (41.19 %)
EPS:	$-0.0447

FY	2023
Ingresos:	$3.51M
Beneficio Bruto:	$1.44M (41.19 %)
EPS:	$-0.0447

FY	2022
Ingresos:	$170 369
Beneficio Bruto:	$-1.89M (-1 111.18 %)
EPS:	$-0.0374

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.503

Financial Reports:

No articles found.

Immutep Limited

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.